These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 6442624

  • 1. Mitomycin C and 5-fluorouracil as second choice treatment in advanced breast cancer patients.
    Ardizzoni A, Pronzato P, Conte PF, Rosso R.
    Chemioterapia; 1984 Apr; 3(2):83-5. PubMed ID: 6442624
    [Abstract] [Full Text] [Related]

  • 2. Chemotherapy with mitomycin-C, epidoxorubicin and vinblastine in CMF failing breast cancer patients.
    Pronzato P, Amoroso D, Bertelli G, Queirolo P, Sertoli MR, Rosso R.
    Anticancer Res; 1990 Apr; 10(6):1743-5. PubMed ID: 2126683
    [Abstract] [Full Text] [Related]

  • 3. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A, Extra JM, Espié M, Cuvier C, Marty M.
    In Vivo; 1998 Apr; 12(5):559-62. PubMed ID: 9827368
    [Abstract] [Full Text] [Related]

  • 4. Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
    Francini G, Petrioli R, Messinese S, Pozzessere D, Marsili S, Correale P, Sabatino M, Fiaschi AI.
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):271-6. PubMed ID: 12357300
    [Abstract] [Full Text] [Related]

  • 5. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD, Jolivet J, Birch R, Hopkins LG, Greco FA.
    Cancer; 1997 Feb 15; 79(4):740-8. PubMed ID: 9024712
    [Abstract] [Full Text] [Related]

  • 6. Activity and tolerability of a combined palliative chemotherapy with mitomycin C, folinate, and 5-Fluorouracil in patients with advanced breast cancer after intensive pretreatment: a retrospective analysis.
    Eichbaum MH, Gast AS, Schneeweiss A, Bruckner T, Sohn C.
    Am J Clin Oncol; 2007 Apr 15; 30(2):139-45. PubMed ID: 17414462
    [Abstract] [Full Text] [Related]

  • 7. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U, Wilke H, Seeber S.
    Semin Oncol; 1996 Oct 15; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Clinical evaluation of adriamycin for advanced breast cancer (3)--a joint study by 26 institutes on the CAF and CMcF treatment].
    Kubo K, Abe O, Izuo M, Enomoto K, Koyama H, Sakai K, Terasawa T, Tominaga T, Nomura Y.
    Gan To Kagaku Ryoho; 1983 Dec 15; 10(12):2523-31. PubMed ID: 6689117
    [Abstract] [Full Text] [Related]

  • 10. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
    Pieńkowski T, Jagiello-Gruszfeld A.
    Int J Clin Pharmacol Res; 2001 Dec 15; 21(3-4):111-7. PubMed ID: 12067140
    [Abstract] [Full Text] [Related]

  • 11. [Intra-arterial chemotherapy in locally advanced or recurrent breast neoplasms].
    Morandi C, Colopi S, Cantore M, Molani L, Calzona C, Reggiani G, Amadori M, Smerieri F, Pellecchi G.
    Radiol Med; 1996 Dec 15; 92(1-2):101-4. PubMed ID: 8966246
    [Abstract] [Full Text] [Related]

  • 12. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen.
    Orlando L, Colleoni M, Curigliano G, Nolè F, Ferretti G, Masci G, Peruzzotti G, Minchella I, Intra M, Veronesi P, Viale G, Goldhirsch A.
    Anticancer Res; 2001 Dec 15; 21(6A):4135-9. PubMed ID: 11911307
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study.
    Klaassen U, Wilke H, Müller C, Borquez D, Harstrick A, Seeber S.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 17):S17-58-S17-60. PubMed ID: 9374095
    [Abstract] [Full Text] [Related]

  • 15. Mitomycin and tamoxifen versus mitolactol, doxorubicin, and tamoxifen in patients with previously treated breast cancer.
    Falkson G, Gelman RS, Tormey DC, Taylor SG, Falkson HC.
    Cancer Treat Rep; 1985 Oct 15; 69(7-8):755-60. PubMed ID: 4016786
    [Abstract] [Full Text] [Related]

  • 16. Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer.
    Bishop JF, Raghavan D, Woods R, Coates A, Burns I, Jeal PN, Hillcoat BL, Tattersall MN.
    Cancer Treat Rep; 1987 Feb 15; 71(2):191-3. PubMed ID: 2433037
    [Abstract] [Full Text] [Related]

  • 17. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer.
    Cocconi G, DeLisi V, Di Blasio B.
    Cancer Treat Rep; 1982 Jun 15; 66(6):1263-6. PubMed ID: 7083233
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A review of mitomycin regimens in advanced breast cancer therapy.
    Legha SS.
    Clin Ther; 1985 Jun 15; 7(3):286-307. PubMed ID: 3888391
    [Abstract] [Full Text] [Related]

  • 20. A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer.
    Li M, Zhang J, Wang D, Zhong B, Tucker S, Lu C, Cheng J, Cao C, Xu J, Xu J, Pan H.
    Anticancer Drugs; 2009 Nov 15; 20(10):941-5. PubMed ID: 19745719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.